Identification and mechanistic studies of a novel ubiquitin E1 inhibitor
Dana Ungermannova1, Seth J Parker, Christopher G Nasveschuk
1University of Colorado, Boulder, Colorado, CO, USA.
Abstract:
Protein degradation via the ubiquitin-proteasome pathway is important for a diverse number of cellular processes ranging from cell signaling to development. Disruption of the ubiquitin pathway occurs in a variety of human diseases, including several cancers and neurological disorders. Excessive proteolysis of tumor suppressor proteins, such as p27, occurs in numerous aggressive human tumors. To discover small-molecule inhibitors that potentially prevent p27 degradation, we developed a series of screening assays, including a cell-based screen of a small-molecule compound library and two novel nucleotide exchange assays. Several small-molecule inhibitors, including NSC624206, were identified and subsequently verified to prevent p27 ubiquitination in vitro. The mechanism of NSC624206 inhibition of p27 ubiquitination was further unraveled using the nucleotide exchange assays and shown to be due to antagonizing ubiquitin activating enzyme (E1). We determined that NSC624206 and PYR-41, a recently reported inhibitor of ubiquitin E1, specifically block ubiquitin-thioester formation but have no effect on ubiquitin adenylation. These studies reveal a novel E1 inhibitor that targets a specific step of the E1 activation reaction. NSC624206 could, therefore, be potentially useful for the control of excessive ubiquitin-mediated proteolysis in vivo.
Insights
Researchers identified NSC624206, a novel small-molecule inhibitor targeting ubiquitin-activating enzyme (E1). This compound prevents excessive proteolysis of tumor suppressor proteins like p27, offering potential therapeutic applications for cancers and neurological disorders.
Area of Science:
- Biochemistry
- Molecular Biology
- Cellular Biology
Background:
- The ubiquitin-proteasome pathway is crucial for cellular processes and its disruption is linked to diseases like cancer and neurological disorders.
- Excessive degradation of tumor suppressor proteins, such as p27, is observed in aggressive human tumors.
- Targeting protein degradation pathways offers a potential therapeutic strategy for various human diseases.
Purpose of the Study:
- To discover small-molecule inhibitors that prevent the degradation of the tumor suppressor protein p27.
- To elucidate the mechanism of action of identified inhibitors on the ubiquitin-proteasome pathway.
- To identify novel therapeutic agents for controlling excessive protein degradation in vivo.
Main Methods:
- Development of screening assays, including a cell-based screen and two novel nucleotide exchange assays.
- Identification and verification of small-molecule inhibitors, such as NSC624206, that prevent p27 ubiquitination in vitro.
- Detailed mechanistic studies using nucleotide exchange assays to understand the inhibition of ubiquitin-activating enzyme (E1).
Main Results:
- Several small-molecule inhibitors, including NSC624206, were identified.
- NSC624206 was verified to prevent p27 ubiquitination in vitro.
- NSC624206 was shown to antagonize ubiquitin-activating enzyme (E1) by specifically blocking ubiquitin-thioester formation, not adenylation.
Conclusions:
- NSC624206 is a novel inhibitor of ubiquitin-activating enzyme (E1) that targets a specific step in the E1 activation reaction.
- The identified inhibitor demonstrates potential for controlling excessive ubiquitin-mediated proteolysis in vivo.
- This research provides a new tool for investigating and potentially treating diseases associated with aberrant protein degradation.
